Peptides in Metabolic Research: What the Published Studies Show
This overview covers three research topics in metabolic science: Retatrutide, MOTS-C and Tesamorelin. Their receptor pathways and evidence bases differ. For laboratory research purposes only; not for human therapeutic use.
- ✓Retatrutide (triple GIP/GLP-1/glucagon agonist) showed ~24% body weight reduction at 48 weeks in Phase 2 trials, currently in Phase 3 TRIUMPH programme
- ✓MOTS-C is a mitochondria-derived peptide that activates AMPK, improving insulin sensitivity in rodent models of metabolic dysfunction
- ✓Tesamorelin (GHRH analogue) has Phase 3 data and FDA approval for HIV-associated lipodystrophy, the only GHRH analogue with regulatory approval for a metabolic indication
- ✓All products for research purposes only, October 2024 TGA compounding changes affect GLP-1 class peptides in Australia; see TGA guidance for current regulatory status
In This Article
The Landscape of Metabolic Peptide Research
Metabolic peptide research spans distinct pathways. Retatrutide targets GIP, GLP-1 and glucagon receptors; MOTS-C is studied in mitochondrial and AMPK-related research; Tesamorelin is a GHRH analogue studied within the GH–IGF-1 axis. Evidence for one compound cannot be transferred to another.
These compounds are not interchangeable, they target different receptor systems, produce different metabolic signatures in research models, and carry different regulatory and compliance considerations in Australia. Understanding the mechanistic distinctions is essential for designing protocols that isolate specific pathways of interest.
Retatrutide (Triple Receptor Agonism in Adiposity Research)
Retatrutide (LY3437943) has agonist activity at GIP, GLP-1 and glucagon receptors. The contribution of each pathway requires evidence from appropriately designed mechanistic studies. See the Retatrutide research overview for the cited research.
The 2023 phase 2 trial in adults with obesity reported mean body-weight reduction of approximately 24% at 48 weeks in the highest dose group. This result belongs to the studied intervention and trial population. Jastreboff et al., 2023.
For researchers: Retatrutide's unique GCGR component makes it the most mechanistically distinct of the three GLP-1 class compounds covered here. Research comparing triple versus dual versus single agonism is an active area, particularly for NASH/liver fat endpoints where the GCGR contribution appears most differentiated.
MOTS-C (Mitochondria-Derived Metabolic Regulation via AMPK)
MOTS-C is a mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome, making it one of a newly characterised class of mitochondria-derived peptides (MDPs) with systemic signalling functions. Its primary studied mechanism is AMPK (AMP-activated protein kinase) activation, a central energy-sensing enzyme that regulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
Research interest in MOTS-C extends across several metabolic contexts: insulin sensitisation in skeletal muscle (preclinical rodent models with diet-induced obesity), exercise-mimetic effects on muscle metabolism, and age-related metabolic decline. A 2021 study (Lee et al.) documented circulating MOTS-C levels declining with age in humans and showed that MOTS-C administration improved physical performance and metabolic parameters in aged mice, generating interest in its role in ageing-related metabolic dysregulation.
MOTS-C's AMPK mechanism is entirely distinct from incretin receptor signalling, making it a complementary research compound for studies examining non-incretin routes to improved insulin sensitivity and mitochondrial function. It is not subject to the October 2024 TGA GLP-1 compounding changes.
Tesamorelin (GH-Axis Approach to Visceral Adiposity Research)
Tesamorelin is a synthetic GHRH analogue, the complete 44-amino acid sequence of native GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. It stimulates pituitary GH secretion via the GHRH receptor, leading to downstream IGF-1 elevation. Unlike CJC-1295, which uses a DAC modification for very long-acting GH stimulation, Tesamorelin has a shorter half-life (~26 minutes), producing more pulsatile GH release that more closely approximates physiological patterns.
Tesamorelin's relevance to metabolic research is partly anchored by its regulatory history: it received FDA approval in 2010 for HIV-associated lipodystrophy, specifically visceral adiposity secondary to antiretroviral therapy, making it the only GH secretagogue with a regulatory approval for a metabolic adiposity indication. Phase 3 data demonstrated significant reductions in visceral adipose tissue (VAT) as measured by CT, with effects specific to visceral (not subcutaneous) fat compartments.
For researchers studying the GH/IGF-1 axis and its relationship to adipose tissue distribution, particularly visceral fat specifically, rather than total body fat, Tesamorelin provides a well-characterised GHRH agonist tool with established clinical reference data.
Metabolic Research Peptides (Quick Reference)
| Compound | Receptor Target | Key Research Focus | Human Data |
|---|---|---|---|
| Retatrutide | GIP-R + GLP-1R + GCGR (triple) | Adiposity, MASH/NASH, energy expenditure | Phase 3 ongoing (TRIUMPH) |
| MOTS-C | AMPK (mitochondria-derived) | Insulin sensitivity, ageing, exercise mimetic | Primarily preclinical |
| Tesamorelin | GHRHR (GH axis) | Visceral adiposity, HIV lipodystrophy | FDA-approved (lipodystrophy); Phase 3 data |
Frequently Asked Questions
Key References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. [Tesamorelin Phase 3]